Researcher

Dr James Edward Thompson

Biography

Dr James Thompson is a robotic, laparoscopic, endoscopic and open urological surgeon with sub-speciality expertise in the diagnosis and treatment of prostate and bladder cancer using the latest techniques in robotic surgery, focal therapy, MRI and PSMA-guided biopsy and novel drugs that may improve cure rates.
 

Dr Thompson completed a 6-year Royal Australasian College of Surgeons accredited training program in all aspects of general urology....view more

Dr James Thompson is a robotic, laparoscopic, endoscopic and open urological surgeon with sub-speciality expertise in the diagnosis and treatment of prostate and bladder cancer using the latest techniques in robotic surgery, focal therapy, MRI and PSMA-guided biopsy and novel drugs that may improve cure rates.
 

Dr Thompson completed a 6-year Royal Australasian College of Surgeons accredited training program in all aspects of general urology. He then completed a post-graduate fellowship in robotic and open uro-oncology at University College London Hospital, then was appointed at UCLH as a consultant robotic and open uro- oncologic surgeon.

In 2018, he accepted an offer to return to Sydney as a staff specialist Uro-Oncologist at St George Hospital and St Vincents Clinic in order to provide state of the art cancer care to the Australian community, and to continue cutting edge cancer research in partnership with the Garvan Institute/ Kinghorn Cancer Centre, APCRC, ANZUP, St George Exosome Research Unit and UNSW.


My Qualifications

BSc (Med) (UNSW)

MBBS (1st Class Honours, UNSW)

FRACS (Urol)

IMGSS (RCS Ed)

PhD (UNSW)


My Research Activities

Invited Journal Reviewer: 
BJU International (Editorial Board Member), The Lancet, Lancet Oncology, European Urology, Journal of Urology, Prostate Cancer Prostatic Diseases, BMC Urology, Asian J Urology
 
Peer-reviewed Journal Publications:

Thompson J, Amin A, Stricker P. MRI improves selection for active surveillance and can be used to extend the interval between biopsies. Eur Urol 2020; ePub online before print.

De Silva S, Lockhart K, … Thompson J.  Chemical shift imaging in the identification of those renal tumours that contain microscopic fat and the utility of multiparametric MRI in their differentiation" has been accepted for publication in Journal of Medical Imaging and Radiation Oncology. 2020. https://doi.org/10.1111/1754-9485.13082.

JE Thompson, A Sridhar; G Shaw, et al. Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation. 
BMC Urology. 2020. BURO-D-19-00460R1. EPub ahead of print.

S. De Silva; K Lockhart; M Moussa… J Thompson. The diagnostic utility of diffusion weighted MRI imaging and ADC ratio to distinguish benign from malignant renal masses: sorting the kittens from the tigers. Jap J Rad 2020 under review. BMIM-D-20-00081.

Algohary A, Thompson J, et al. Combination of Peri-Tumoral and Intra-Tumoral Radiomic Features on Bi-Parametric MRI Accurately Stratifies Prostate Cancer Risk: A Multi-Site Study. Cancers 2020. In press.

Thompson J, Stricker P. Editorial comment on “perioperative outcomes between single port and multiport robotic-assisted radical prostatectomy: a single institutional experience”. J Urol 2020 ePub 24/02/2020..

Amin A, …Thompson, J.  The MRI in active surveillance ‘MRIAS’ trial: Use of baseline mpMRI and saturation biopsy to reduce the frequency of surveillance prostate biopsies. Journal of Urology, 2020 (accepted 4/12/2019 ePub ahead of print).

Blazevski A, … Thompson J, et al. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int 2020 (epub DOI: 10.1111/bju.14951).

Amin A, … Thompson, J… et al.  PRIMARY Trial - A prospective multi-centre cross-sectional study of the additive diagnostic value of gallium-68 prostate specific membrane antigen (PSMA) PET/CT to multiparametric (mp) MRI in the diagnostic setting for men being investigated for prostate cancer: clinical trial protocol
. BJUI 2019.

Blazevski A, … Thompson J, et al. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. Eur Urol Oncol 2019 (DOI: 10.1016/j.euo.2019.04.008).

B Pang, Y Zhu, J Ni, J Thompson, et al. Current progress of extracellular vesicles in prostate cancer early diagnosis. Molecular Cancer 2019. (Epub ahead of Print).

J Wang , J Ni , J Beretov, J Thompson, P Graham, Y Li. Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer. Crit Rev Oncol Haem 2019. (Epub ahead of Print).

Scheltema M, et al.  Diagnostic accuracy of 68Ga-PSMA PET and mpMRI to detect intra-prostatic clinically significant prostate cancer using whole-mount pathology. Impact of the addition of 68Ga-PSMA PET to mpMRI. BJUI 2019 epub  DOI: 10.1111/bju.14794 .

Thompson J, Sridhar A, … Sooriakumaran, P. Pathological landscape following salvage robot-assisted radical prostatectomy after focal high intensity focused ultrasound. J Urol 2019. 
(Also presented as poster presentations at EAU 2018 Copenhagen and BAUS 2018 Liverpool and ERUS 2018 Marseille).  
 
Thompson J, Stricker P. Editorial on Kornberg et al. GPS, PIRADS v2 and progression in men on active surveillance for prostate cancer. J Urol JU-18-930-R1 2019.

Algohary … Thompson JE et al. Radiomic Features on MRI enable risk categorization of prostate cancer patients on active surveillance: preliminary findings. J MRI.  2018 Feb 22. doi:10.1002/jmri.25983.

Thompson JE, Egger S, Böhm M, Siriwardana A, Haynes A, Stricker PD. Superior biochemical recurrence rates are achievable with robotic radical prostatectomy after a long learning curve – follow-up study of a prospective single-surgeon study of more than 2,000 consecutive cases. Eur Urol 2018; 73 (5): 665.

Scheltema MJ, Chang JI, Bohm M…Thompson J et al. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. 2018 Sep; 36(9):1383-1389.

A Siriwardana, J Thompson, P Van Leeuwen, S Doig, A Kalsbeek, L Emmett, W Delprado, D Wong, H Samaratunga, AM Haynes, G Coughlin, P Stricker. Initial multi-centre experience of 68Gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU Int 2017. 120(5): 673-681. Doi: 10.1111/bju.13919.

Thompson JE, Stricker PD. Invited editorial commentary on Borkowetz et al and Faria et al studies in MRI for detection of prostate cancer. Accepted Oct 2017 - in press; Nature Reviews Urology NRU-17-233V1.

Thompson JE, Stricker PD. Diagnostic Accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer. The Lancet. 2017; 389 (10071): 767-768. 

Thompson J, Nathan S. Who should undergo radical prostatectomy – a review of the literature. BJUI Knowledge 2018.

PJ van Leeuwen, A Hayen, JE Thompson… PD Stricker. A Multiparametric Magnetic Resonance Imaging Based Risk Model to Determine the Risk of Significant Prostate Cancer prior to biopsy. BJU Int. 2017 Epub. Doi: 10.1111/bju.13814.

Siriwardana A, Thompson J, Stricker P. Personalising prostate cancer care. Part 2. Current Treatment Options. Medicine Today 2017; 18(3): 28-33.

Siriwardana A, Thompson J, Stricker P. Personalising prostate cancer care. Part 1. Advances in Diagnosis. Medicine Today 2017; 18(2): 29-32.

Siriwardana A, Van Den Bos W, Thompson J, Shnier R, Stricker PD. The role of MRI in prostate cancer: a changing paradigm. Medicine Today 2017; 18(1): 44-46.

W van den Bos, M Scheltema, A Siriwardana, A Kalsbeek, J Thompson, F Ting, M Böhm, A Haynes, R Shnier, W Delprado, P Stricker. Focal irreversible electroporation as primary treatment for prostate cancer. BJU Int Aug 2017 epub. Doi: 10.1111/bju.13983. 

Scheltema M, … Thompson J… Stricker PD. Feasability and safety of focal irreversible electroporation as a salvage treatment for radio-recurrent prostate cancer. BJU Int 2017; 120 Suppl (3): 51-58.

Mazzon G, Sridhar A, Busuttil G, Thompson J, Nathan S, Briggs T, Kelly J, Shaw G. Learning curves for robotic surgery: a review of the recent literature. Curr Urol Rep. 2017; 18(11):89. Doi: 10.1007/s11934-017-0738-z.

Khetrapal P,… Thompson J, …Briggs T. The role of robotics in the invasive management of bladder cancer. Curr Urol Rep. 2017; 18(8):57.

A Siriwardana, JE Thompson, F Ting, W Delprado, P Brenner, D Ende, R Kooner, G O’Neill, C Yuen, S Tiwari, AM Haynes, PD Stricker. Lymph node yield at radical prostatectomy is a predictor of biochemical recurrence-free survival (BFS) in high-risk prostate cancer patients. Prostate Cancer. Manuscript under review, 2017.

Cole Clark D, Siriwardana A, Thompson J, Leslie S, Arianayagam M, Varol C, Yuen C. Robotic cystectomy for bladder cancer: a multi-centre retrospective case series of the Australian experience. ANZ J Surg 2018 (under review).

J Thompson et al. Diagnostic utility of Multiparametric MRI, PCA3 and PHI for Detection of Significant Prostate Cancer in men with previous negative biopsy: a prospective cross-sectional study. Prostate Cancer Prostatic Diseases 2018 (under review).

M Rusu, … J Thompson, P Stricker, A Madabhushi. Computational imaging reveals shape differences between normal and malignant prostates on MRI. Scientific Reports. 2017; 7[41261]. Doi: 10.1038/srep41261.

Ginsburg S, …Thompson J…Madabushi A. Radiomic Features for Prostate Cancer Detection on MRI differ between the Transition and Peripheral Zones: Preliminary Findings from a Multi-institutional Study. Journal Magnetic Resonance Imaging. 2017; 46(1): 184-193. 

J Thompson, Van Leeuwen, D Moses, R Shnier, P Brenner, W Delprado, L Ponsky, M Pulbrook, M Bohm, A Haynes, J Matthews, A Hayen, P Stricker. The diagnostic performance of Multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urol 2016. 192: 67-74.

Van Leeuwen P, Siriwardana A… Thompson J, et al. Predicting low-risk prostate cancer from transperineal saturation biopsies. Prostate Cancer. 2016. Doi:10.1155/2016/7105678. 

M Tran, J Thompson, M Bohm, … P Stricker. Combination of multi-parametric magnetic resonance imaging (mp-MRI) and transperineal template-guided mapping biopsy (TTMB) of the prostate to identify candidates for hemi-ablative focal therapy. BJU Int. 2016; 117(1): 48-54.

Ting F, Van Leeuwen P, Thompson J, et al. Assessment of the performance of magnetic resonance imaging/ ultrasound fusion guided prostate biopsy against a combined targeted plus systematic biopsy approach using 24-core transperineal saturation template mapping prostate biopsy. Prostate Cancer. 2016. Doi: 10.1155/2016/ 3794738. 

J Thompson, A Hayen, A Landau, A Haynes, A Kalapara, J Ischia, J Matthews, M Frydenberg, P Stricker. Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer. BJUI 2015; 115(6): 884-891.

J Thompson, D Moses, R Shnier, … P Stricker. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer & could reduce unnecessary biopsies and over detection: a prospective study. J Urol 2014. 192: 67-74.

J Thompson, A Hayen, P Stricker. Reply from Authors to El Shater Bosaily et al regarding letter to the editor re: Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer & could reduce unnecessary biopsies and over detection: a prospective study. J Urol 2015; 193(2): 735-736.

Thompson, J; Egger, S; Böhm, M; Haynes, A; Matthews, J; Rasiah, K; Stricker, P. Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve – a prospective single-surgeon study of 1,552 consecutive cases. European Urology 2014; 65(1): 521-531.

Thompson, J; Egger, S; Stricker, P. Reply from authors regarding Rao et al re: Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve – a prospective single-surgeon study of 1,552 consecutive cases. European Urology 2014. 

Thompson J, Lawrentschuk N, Frydenberg M, Thompson L, Stricker P. Review of the role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJUI 2013; 112 Suppl 2:6-20.

Thompson J, Lawrentschuk N, Frydenberg M, Thompson L, Stricker P. USANZ MRI working party position statement on the role of magnetic resonance imaging in the diagnosis & management of prostate cancer. USANZ; Published online Oct 2012.

Thompson J, Galketiya K, Lim J. Antiplatelets in general surgery: a survey of current practise amongst general surgeons and literature review. ANZ J Surg 2012.

Thompson J, Collett L, Langbart M, Purcell N, Boyd S, Yuminaga Y, Ossolinski G, Susanto C, McCormack A. Using the ISBAR handover tool in junior medical officer handover: a trial in an Australian tertiary hospital. Postgrad Med J 2011; 87: 340-4. PubMed PMID: 21310805.  

 

Selected conference podium presentations: 

Thompson J, …Kelly JD. Salvage RARP post HIFU for prostate cancer. Accepted for EAU Conference March 2018.

Shaw, G, … Thompson J…Neal D. Effects of single dose simadjuvant degarelix 240mg on 5 year treatment failure rate after radical prostatectomy for high risk prostate cancer. Accepted for EAU Conference 2018.

Sridhar A, … Thompson J, Briggs T. Surgical Techniques to optimize early urinary continence recovery post robot assisted radical prostatectomy for prostate cancer. Presented EAU ERUS Conference 2017. Eur Urol suppl; 16(6). Doi: 10.1016/S1569-9056(17)31517-8.

Thompson J. The role of MRI and PSMA in diagnosis and management of prostate cancer. Invited lecture – USANZ Victorian ASM, 2015.

Thompson, J; Egger, S; Böhm, M; Haynes, A; Matthews, J; Rasiah, K; Stricker, P. Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve – a prospective single-surgeon study of 1,552 consecutive cases. Presented at NSW USANZ ASM 2013.

J Thompson, D Moses, R Shnier, P Brenner, W Delprado, L Ponsky, A Haynes, J Matthews, A Hayen, P Stricker. Magnetic resonance imaging detects significant prostate cancer & could reduce unnecessary biopsies and overdetection: results from a prospective cross-sectional study. Presentations at USANZ 2014, AUA 2013, USANZ 2013, MRI Conference 2013.

J Thompson, J Dargan, L Hayden, N Lalak, K Haghighi, P Mancuso, Paul Salmon, Paul Gassner. Stone Free Rates, Complications, Length Of Stay And Costs Associated With Pyeloscopy Vs Pcnl For Intermediate Size Renal Calculi. USANZ State Conference 2014 and Australasian ASM 2015 Presentations.

J Thompson, N Mehan, K Easter, M Yuhico, C Whelan, T Nicholson. Comparison of the accuracy of 12-, 16- and 20-core trans-rectal biopsy for detection of significant prostate cancer and correlation with radical prostatectomy. USANZ NSW Conference Presentations, 2013 and 2014.

Thompson J, Oneill C, Suliburk J, Sywak M, Sidhu S, Delbridge L. Mediastinal parathyroids: selection of operative approach based on pre-operative imaging modalities. ANZ J Surg. 2011 ASC Abstracts.
 

 

Prostate Cancer, current studies involved in include:

- The PRIMARY trial: world-first multicentre Australasian prospective study of Ga-68 PSMA-PET CT added to mpMRI prior to diagnostic biopsy for the detection of prostate cancer.

- DETECT trial: world-first multicentre prospective first in human trial of 99m Tc-PSMA guided ePLND during robotic prostatectomy for men suspected of lymph node metastasis.

- LEEP trial: phase 2 multicentre RCT of a CDK4/6 cell cycle inhibitor prior to radical prostatectomy for high-risk Prostate cancer.

- PROTEUS trial: phase 3 multinational RCT of apalutamide (novel anti-androgen) plus ADT prior to radical prostatectomy for high-risk Prostate cancer.

- MRIAS trial: prospective single-arm trial of MRI plus baseline transperineal saturation biopsy to replace confirmatory biopsy during Active Surveillance for low-risk Prostate cancer

- MAGNIFI trial: prospective cross-sectional comparative study of PSMA-PET vs Combidex Ferro-magnetic Nano-particle MRI for pre-operative lymph node staging prior to radical prostatectomy for high-risk prostate cancer.

- FIRE trial: prospective multicentre single arm trial of salvage focal Irreversible Electroporation for prostate cancer local recurrence after radiotherapy.

- Comparative evaluation of the predictive accuracy of Index vs Composite score at biopsy/ RP to predict recurrence after radical prostatectomy

- Epigenetic methylation markers to predict out-of-field recurrence after focal ablative therapy for prostate cancer.

- Comparative medium-term outcomes of active surveillance for G3+4 using standard transracial vs transperineal saturation biopsy

- Multicentre analysis of the effect of increasing age on continence recovery after radical prostatectomy: a collaborative Garvan/ PCOR-Vic analysis using prospective, independently collected QOL data.

- Prospective evaluation of Exosomes in blood and urine to improve the detection of prostate cancer and prediction of recurrence after treatment.

- Outcomes of salvage RARP for locally recurrent prostate cancer after focal IRE.

- Functional and Oncologic Outcomes of treatment for apical prostate tumours with focal IRE.

- Immunostimulatory effects of IRE treatment on prostate cancer and implications for immune-recognition and destruction of micro-metastasis.

 

Bladder Cancer, current studies involved in include:

- iROC multicentre randomised trial comparing of robotic vs open radical cystectomy with intra-corporeal urinary diversion (UCLH-UK).

- POTOMAC international randomised trial of PD-1 immunotherapy and/ or BCG for high risk Non-muscle invasive bladder cancer.

- BCG-MMC ANZUP randomised trial of MMC in addition to BCG for high risk Non-muscle invasive bladder cancer.

- Multi-centre prospective study of Pre-TURBT mpMRI in the detection of muscle invasive Bladder cancer in Cystoscopy-naive patients presenting with a bladder mass.

- THOR international randomised trial of erdafitinib FGFR receptor antagonist for treatment of recurrent metastatic bladder cancer after chemotherapy.

- phase 1 international randomised trial of Sting Agonist immuno-therapy (stimulator of interferon) for intermediate risk non-muscle invasive bladder cancer.

- THOR-2 phase 2/3 international randomised trial of erdafitinib for high risk BCG unresponsive non-muscle invasive bladder cancer.

- Prospective pilot evaluation of multi-parametric MRI prior to TURBT for T-staging of Bladder masses and identification of muscle-invasive bladder cancer.

View less

Location

1) Darlinghurst: Suite 905, St Vincents Clinic, 430 Victoria St,
2) CBD: Level 7, 26 College St, Sydney, College St Specialists
3) Hurstville: Suite 4/Lvl 1 Hurstville Private, 37 Gloucester Rd
4) Garvan Institute/ Kinghorn Cancer Centre: Level 6, Prostate Cancer Research Program, Localised Group
5) Kogarah: Dept of Urology, Pelvic Floor Unit, St George Hospital, South St

Contact

+61-2-8046-8050
+61-2-8046-8090

Publications

by Dr James Edward Thompson

ORCID as entered in ROS